NCT00410787View on ClinicalTrials.gov

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

Not specified

Study Completion Date

April 30, 2002

Conditions
Analgesics, OpioidPain
Interventions
DRUG

OROS hydromorphone HCI (slow release)

All Listed Sponsors
lead

Alza Corporation, DE, USA

INDUSTRY

NCT00410787 - Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain | Biotech Hunter | Biotech Hunter